Celldex Therapeutics Plunges 11.85% on Earnings Miss

On April 7, 2025, Celldex Therapeutics experienced a significant drop of 11.85% in pre-market trading, reflecting a notable decline in investor sentiment.

Celldex Therapeutics has received a "Moderate Buy" recommendation from nine brokerages, with a mix of hold, buy, and strong buy ratings. The average 12-month target price among analysts is $54.33. Several brokerages have recently issued reports on the company, with varying price targets and ratings. UBS Group set a "buy" rating with a $44.00 price target, while HC Wainwright maintained a "buy" rating with an $80.00 price objective. Cantor Fitzgerald reiterated an "overweight" rating with a $67.00 target price. Goldman Sachs reduced their price target to $36.00 with a "neutral" rating, and Morgan Stanley issued an "overweight" rating with a $46.00 target price.

Several large institutional investors have adjusted their positions in Celldex Therapeutics. BNP Paribas Financial Markets increased its holdings by 293.2%, now owning 28,181 shares. UBS AM lifted its position by 6.5%, owning 102,595 shares. Wellington Management Group LLP grew its position by 14.5%, now owning 9,243,599 shares. XTX Topco Ltd acquired a new stake valued at $1,561,000, and Y Intercept Hong Kong Ltd increased its position by 11.5%, now owning 30,538 shares. Corebridge Financial Inc. reduced its stake by 7.0% during the fourth quarter.

Celldex Therapeutics reported earnings per share of ($0.71) for the quarter, beating analysts' estimates of ($0.73). The company had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. Revenue for the quarter was $1.18 million, slightly below the consensus estimate of $1.25 million. Analysts predict that Celldex Therapeutics will post -2.48 EPS for the current fiscal year.